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Abstract: PURPOSE: Brivanib is a dual inhibitor of vascular-endo-
thelial growth factor and ﬁbroblast growth factor receptors that
are implicated in the pathogenesis of hepatocellular carcinoma
(HCC). Our multinational, randomized, double-blind, phase III trial
compared brivanib with sorafenib as ﬁrst-line treatment for HCC.
PATIENTS AND METHODS: Advanced HCC patients who had no
prior systemic therapy were randomly assigned (ratio, 1:1) to receive
sorafenib 400 mg twice daily orally (n = 578) or brivanib 800 mg
once daily orally (n = 577). Primary end point was overall survival
(OS). Secondary end points included time to progression (TTP), objec-
tive response rate (ORR), disease control rate (DCR) based on modi-
ﬁed Response Evaluation Criteria in Solid Tumors (mRECIST), and
safety.
RESULTS: The primary end point of OS noninferiority for brivanib
versus sorafenib in the per-protocol population (n = 1150) was not
met (hazard ratio [HR], 1.06; 95.8% CI, 0.93 to 1.22), based on the
prespeciﬁed margin (upper CI limit for HR 61.08). Median OS was
9.9 months for sorafenib and 9.5 months for brivanib. TTP, ORR,
and DCR were similar between the study arms. Most frequent grade
3/4 adverse events for sorafenib and brivanib were hyponatremia
(9% and 23%, respectively), AST elevation (17% and 14%), fatigue
(7% and 15%), hand-foot-skin reaction (15% and 2%), and hyperten-
sion (5% and 13%). Discontinuation as a result of adverse events
was 33% for sorafenib and 43% for brivanib; rates for dose reduction
were 50% and 49%, respectively.
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E-mail address: Rﬁnn@mednet.ucla.edu (R.S. Finn).CONCLUSION: Our study did not meet its primary end point of OS
noninferiority for brivanib versus sorafenib. However, both agents
had similar antitumor activity, based on secondary efﬁcacy end
points. Brivanib had an acceptable safety proﬁle, but was less well-
tolerated than sorafenib.
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Abstract: PURPOSE: Brivanib is a selective dual inhibitor of vascu-
lar endothelial growth factor and ﬁbroblast growth factor receptors
implicated in tumorigenesis and angiogenesis in hepatocellular car-
cinoma (HCC). An unmet medical need persists for patients with
HCC whose tumors do not respond to sorafenib or who cannot toler-
ate it. This multicenter, double-blind, randomized, placebo-con-
trolled trial assessed brivanib in patients with HCC who had been
treated with sorafenib.
PATIENTS AND METHODS: In all, 395 patients with advanced HCC
who progressed on/after or were intolerant to sorafenib were ran-
domly assigned (2:1) to receive brivanib 800 mg orally once per
day plus best supportive care (BSC) or placebo plus BSC. The primary
end point was overall survival (OS). Secondary end points included
time to progression (TTP), objective response rate (ORR), and disease
control rate based on modiﬁed Response Evaluation Criteria in Solid
Tumors (mRECIST) and safety.
RESULTS:Median OSwas 9.4 months for brivanib and 8.2 months for
placebo (hazard ratio [HR], 0.89; 95.8% CI, 0.69 to 1.15; P = .3307).
Adjusting treatment effect for baseline prognostic factors yielded an
OS HR of 0.81 (95% CI, 0.63 to 1.04; P = .1044). Exploratory analyses
showed a median time to progression of 4.2 months for brivanib
and 2.7 months for placebo (HR, 0.56; 95% CI, 0.42 to 0.76;
P < .001), and an mRECIST ORR of 10% for brivanib and 2% for placebo
(odds ratio, 5.72). Study discontinuation due to treatment-related
adverse events (AEs) occurred in 61 brivanib patients (23%) and nine
placebo patients (7%). The most frequent treatment-related grade 3 to
4 AEs for brivanib included hypertension (17%), fatigue (13%),
hyponatremia (11%), and decreased appetite (10%).
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CONCLUSION: In patients with HCC who had been treated with
sorafenib, brivanib did not signiﬁcantly improve OS. The observed
beneﬁt in the secondary outcomes of TTP and ORR warrants further
investigation.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Hepatocellular carcinoma (HCC) remains a major health problem
worldwide, and is the sixth most common cancer and third lead-
ing cause of cancer-related mortality globally [1]. The develop-
ment of systemic agents in advanced hepatocellular carcinoma
(HCC) has been a challenge. The results of the SHARP study and
approval of sorafenib in 2007 was a giant step-forward in our
management of the disease and how we design and conduct
studies for this population [2]. However, since then we have been
mired in numerous negative phase III studies [3]. One of the ﬁrst
agents to be evaluated in the post sorafenib era was brivanib, an
oral, potent selective inhibitor of both the ﬁbroblast growth fac-
tor (FGF) and vascular endothelial growth factor (VEGF) family of
receptors (Table 1) [4]. Laboratory evidence suggests that both
pathways play a role in the pathogenesis of HCC and, in context
of the FGFR family, in the resistance to VEGF driven angiogenesis
[5]. Despite encouraging phase II data, enpoints were not met in
two randomised phase III registration studies (Table 2). To avoid
similar disappointment in the future, we should look carefully at
these studies to identify potential ﬂaws in trial design and
assumptions. Given that these are two different populations of
patients, the front-line and second-line groups should be consid-
ered separately.
Brivanib was initially evaluated in two single-arm open label
phase II studies of patients with advanced HCC. The front-line
study enrolled 55 patients with advanced HCC (BCLC B/C
11%/89%) which were treated in the study with the primary
Open access under CC BY-NC-ND license.Table 1. Brivanib targeted tyrosine kinases and inhibition proﬁle.
Tyrosine kinase IC50 (nM) of brivanib 
VEGF-R1 390
VEGF-R2 34
VEGF-R3 10
Flk-1 23
FGF-R1 148
FGF-R2 125
Tie-2 445
Table 2. Comparison of brivanib’s efﬁcacy in phase II and phase III studies.
Phase II
Front-line*
Phase III
BRISK-FL^
DCR (%) 51 66
TTP (mo) 2.8 4.2
PFS (mo) 2.7 n.r.
mOS (mo) 10 9.5
⁄Modiﬁed WHO criteria per independent radiology review.
^Modiﬁed RECIST criteria.
n.r., not reported.
DCR, disease control rate; TTP, time to progression; PFS, progression free survival; mOS
948 Journal of Hepatology 201objective being 6-month progression-free survival (PFS) and pro-
gression free survival rate, and the secondary objectives of
tumour response rate, median progression free and overall sur-
vival, and safety tolerability [6]. Using the modiﬁed World Health
Organization Criteria (mWHO) the 6-month progression free sur-
vival (PFS) rate was 18.2% (95% CI, 9.1–30.9%), median PFS was
2.7 months (95% CI, 1.4–3.0) time to progression (TTP) was
2.8 months (95% CI, 1.4–3.5), and median overall survival (OS)
was 10 months (95% CI, 6.8–15.2 months). Given the control
arm from SHARP (placebo), these data would suggest that briva-
nib is an active drug in HCC, though if compared to the experi-
mental arm in SHARP, it would seem comparable to sorafenib
in efﬁcacy. However, the brivanib study enrolled 64% Asian
patients. In that context, if these efﬁcacy data were compared
to the Asia-Paciﬁc sorafenib phase III study [7], a median OS of
10 months compares very favourably to the median OS of
6.5 months seen in the sorafenib arm in that study. With regard
to toxicity, the adverse effects with brivanib were generally
manageable with fatigue, hypertension, diarrhoea, nausea, and
anorexia being most common and notably, the hand-foot skin
reaction common with sorafenib, is uncommon with brivanib.
After sorafenib’s approval for front-line therapy, the brivanib
study was amended and evaluated brivanib in patients with pro-
gression on one line of prior therapy [8]. Again, this was an open
label single-arm study. 46 patients were enrolled, 94% of them
having received prior sorafenib, and again the majority being
BCLC C (96%) and Asian (67%). Median TTP per mWHO criteria
was 1.77 months (95% CI, 1.38–4.01), median PFS 2.73 months
(95% CI, 1.41–3.91) and median OS was 9.79 months (95% CI,
5.52–13.57). For the ﬁrst time, in a newly deﬁned population of
HCC patients, for those that had prior sorafenib, we were seeing
a median OS of almost 10 months; a number that would not have
been expected from interpreting the SHARP or Asia-Paciﬁc data-
sets when comparing the differences between median OS and
median TTP. One could have postulated that the median OS after
stopping sorafenib was approximately 5 months from the SHARP
study and just under 4 months in the Asia-Paciﬁc study, and so
the OS of 9.79 with brivanib was provocative in a population of
patients with a great unmet need.
In addition, both phase II studies included an assessment of
response using the modiﬁed RECIST criteria for HCC in an attempt
to better capture the clinical activity of brivanib [9]. With these
data in hand, three global phase III randomised studies were per-
formed with brivanib in HCC; a front-line study (BRISK-FL), a
post-sorafenib study (BRISK-PS), and a third in combination with
chemoembolisation (BRISK-TA).
The ﬁrst randomised second-line phase III study in the post
sorafenib era to present was the BRISK-PS study [10]. This wasPhase II
Second-line*
Phase III
BRISK-PS^
45.7 61
1.77 4.2
2.0 n.r.
9.79 9.4
, median overall survival.
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a global phase III, double-blind placebo control study of 395
patients randomised 2:1 that had progressed on or after sorafenib
or were intolerant to sorafenib. The primary endpoint for the
study was OS with a minimum hazard ratio of 0.78 being
required for the study to be considered positive. Patients were
stratiﬁed based on reason for sorafenib discontinuation and other
strata commonly used in front-line HCC studies such as ECOG-
performance status and the presence of extrahepatic spread,
and/or vascular invasion. While the study was generally well bal-
anced for these strata, there was an imbalance favouring the con-
trol arm in the number of patients that had vascular invasion,
which was masked by the fact that the majority of patients had
extrahepatic spread. In addition baseline a-fetoprotein (AFP),
while not included in the stratiﬁcation but a recognised negative
prognostic factor in HCC, was increased in patients receiving briv-
anib. This study missed its primary endpoint; while median OS
was better with brivanib, 8.2 months with placebo vs. 9.4 months
with brivanib (HR, 0.89; 95.8% CI, 0.69–1.15; p = 0.3307) this was
not statistically signiﬁcant. Importantly, median OS in the phase
III study was similar to that seen in the phase II for this popula-
tion (9.4 months vs. 9.70). Time to progression (TTP) was signiﬁ-
cantly increased with brivanib as well as other secondary
endpoints such objective response rate and disease control rate,
all assessed using mRECIST. The side effect proﬁle of brivanib
was similar as in the phase II studies and was accompanied by
a high rate of dose interruptions and reductions and a discontin-
uation rate of 23% secondary to AEs.
Similarly, the BRISK-FL study did not meet its primary end-
point of non-inferiority in improving OS compared to sorafenib
[11]. This study enrolled over 1100 patients and randomised
them 1:1 in a double-blind fashion to brivanib or sorafenib and
stratiﬁed them similarly as the SHARP study; by ECOG-PS, extra-
hepatic spread, and/or vascular invasion, and study site. Again,
median OS with brivanib was similar as in the phase II study,
9.5 months vs. 10 months in phase III and II, respectively. How-
ever, this number did not differ signiﬁcantly from the sorafenib
survival of 9.9 months (HR, 1.06; 95.8% CI, 0.93–1.22) and
exceeded the upper-limit HR 95% CI of 1.08 to indicate non-infe-
riority. Unlike the BRISK-PS study, secondary endpoints were
similar using mRECIST in the BRISK-FL study, though the ORR
with sorafenib of 9% with mRECIST was higher than that reported
in the SHARP study using RECIST (2%). Again, the AE proﬁle of
brivanib was similar to the phase II studies. While the frequency
of dose adjustments and interruptions was similar between the
two arms, there were more discontinuations with brivanib due
to adverse events, 43% with brivanib as compared to 33% with
sorafenib. This fact highlights another relevant fact for drug
development in HCC: systemic toxicity is not as well tolerated
as in other malignancies. The failure of sunitinib in this popula-
tion also echoes this observation [12].
So what can we learn from the development of brivanib? One,
control arms are important, not only for phase III studies but for
phase II as well. It could be argued that a randomised phase II
study would have identiﬁed the equivalence of brivanib to
sorafenib in the front-line setting making the BRISK-FL study less
appealing. In addition, for the BRISK-PS study, a randomised
phase II study would have given a better sense of the actual sur-
vival of the placebo group and possibly identify other important
factors effecting survival in the post-sorafenib setting. Second,
and along those lines, strata used in the front-line setting may
not be applicable in the second-line setting. Perhaps, separatingJournal of Hepatology 201extrahepatic-spread from vascular invasion is an important con-
sideration in the second-line setting? Only recently, two publica-
tions identiﬁed prognosticators of outcome after sorafenib
progression [13,14], one of which was just meeting the inclusion
for a second-line study (i.e., selection bias). Third, is developing a
better assessment tool for beneﬁt in clinical trials with molecular
targeted therapeutics? From the SHARP study and these prospec-
tive trials, it would appear that neither response by RECIST nor
mRECIST correlates with outcome in HCC and further reﬁnement
of imaging endpoints need to be developed. In addition, perhaps
it is time to move beyond anti-angiogenic agents in HCC. To date,
no agents in this class, like brivanib, have been able to improve
on sorafenib in the front-line or improve survival in the sec-
ond-line setting. This is not to say these agents might not have
done better than placebo in the front-line but as it stands, they
need to do better than sorafenib or at least do as well with a more
favourable toxicity proﬁle. After sorafenib, we need to demand
both a strong clinical rationale and biologic rationale to move
agents with a similar mechanism of action into this space. Finally,
drug development in HCC has suffered from the clinical heteroge-
neity of the disease and its molecular heterogeneity. More work
on predictive markers of response needs to be done in HCC. While
an ‘‘all-comers’’ approach worked for sorafenib, if we want to
move forward in HCC with molecular therapeutics, we need not
only better clinical trial tools and design but we also need to
better select patients most likely to beneﬁt from a given agent.Conﬂict of interest
RSF has served as a consultant to Bristol Myers Squibb, Onyx,
Bayer, and Novartis.
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